Riverview Trust Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Riverview Trust Company’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-78	Closed	-$21.1K	–	241
2025 Q1	$21.1K	Hold	78	–	–	0.02%	411
2024 Q4	$18.4K	Buy	78 +75	+2,500%	+$19.7K	0.02%	505
2024 Q3	$825	Buy	+3	New	+$781	﹤0.01%	671
2024 Q2	–	Sell	-104	Closed	-$15.5K	–	627
2024 Q1	$15.5K	Buy	+104	New	+$17.3K	0.01%	583
2023 Q3	–	Sell	-67	Closed	-$12.7K	–	678
2023 Q2	$12.7K	Buy	+67	New	+$13.3K	0.01%	641
2022 Q2	–	Sell	-94	Closed	-$15K	–	711
2022 Q1	$15K	Buy	+94	New	+$14.3K	0.01%	598

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Riverview Trust Company's ALNY Position: Q2 2025 in Review

Riverview Trust Company sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 78 shares — an estimated $21.1K sold.

Riverview Trust Company first reported a position in ALNY in Q1 2022 and held it in 6 quarters. The position peaked at $21.1K in Q1 2025. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

Riverview Trust Company reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Riverview Trust Company sold 78 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $21.1K.
Riverview Trust Company first reported a position in Alnylam Pharmaceuticals in Q1 2022 and held it in 6 quarters.
Riverview Trust Company's Alnylam Pharmaceuticals position peaked at $21.1K in Q1 2025.
654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Riverview Trust Company's 13F filing for Q2 2025, filed 21 Jul 2025.